Our experience with the management of superficial bladder cancer (Transitional Cell Ca), the role of adjuvant intravesical BCG therapy
DOI:
https://doi.org/10.21649/akemu.v12i4.958Keywords:
Carcinoma, Transitional Cell. Bladder Cancer. Cystectomy. Administration, Intravesical. BCG Vaccine. Combined Modality Therapy. Bladder Disease. Carcinoma. Antineoplastic Agents.Abstract
We present our experience of 52 patients with bladder cancer. 47 patients (90%) were having superficial bladder disease (Ta, T1) who underwent TURBT followed by intravesical BCG postoperatively, 35 patients (67.3%) completed 6 weeks. Course of intravesical BCG with 10 patients (19.3%) showed recurrence of disease after` six month of follow-up. 4 patients (7.6%) left after 2 weeks of intravesical BCG and 3 patients (5.76%) did not take BCG therapy. These patients hade invasive disease and underwent radical cystectomy and two patients had metastatic bladder cancer disease which were advised systemic palliative treatment. We found intravesical BCG as effective and successful adjuvant therapy for superficial bladder cancer.
Downloads
Published
How to Cite
Issue
Section
License
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk